Article Abstract

Cardio-oncology program: a much needed collaboration in the Middle East

Authors: Wael AlJaroudi

Abstract

Cancer remains the second leading cause of death in the Western world (1,2), with increasing numbers in the Middle East. Over the last decade, there have been new chemotherapeutic agents such as monoclonal antibodies that target human epidermal growth factor receptor tyrosine kinase inhibitor (TKI) and new generation of anthracyclines that are showing promising results (3,4). However, these agents carry potential cardiotoxic effect (type I and type II) that may result in heart failure (5-7).

Refbacks

  • There are currently no refbacks.